CNS Pharmaceuticals surged 242.36% in one week on Berubicin glioblastoma developments, but the move largely reflects already-telegraphed topline data rather than future anticipation. The company remains pre-revenue and single-asset, with a small market capitalization around $6.36 million, a Q1 2024 net loss of $3.50 million, and cash reduced to about $800,000. Despite the rally, the stock is down 42.18% over one year and about 100% over five years on a split-adjusted basis, indicating persistent downside risk. NeOnc Technologies is highlighted for clinical improvements with NEO100, FDA clearance for NEO212, non-dilutive NIH funding, and a strategic partnership. Plus Therapeutics is highlighted for expanding commercial coverage and reimbursement support for its CNSide diagnostic.
"CNS Pharmaceuticals ( NASDAQ:CNSP) is back on every biotech watchlist after a 242.36% one-week ramp tied to its Berubicin glioblastoma story. But here's what you should actually be watching. Holders captured the move; new entrants face tougher math from here. The market cap sits at roughly $6.36 million, the company reported a Q1 2024 net loss of $3.50 million with cash collapsed to about $800,000, and the stock is still off 42.18% over one year and effectively 100% over five years on a split-adjusted basis."
"The defining catalyst, Berubicin topline data, was already telegraphed for the first half of 2025. This week's move resolves that catalyst rather than anticipating it. Pre-revenue, single-asset, cash-starved binaries carry concentrated risk profiles that compound after a triple-digit week. The smarter redirects sit in the same central nervous system oncology lane with deeper pipelines, real funding, and commercial traction the crowd has not priced in."
"NeOnc Technologies ( NASDAQ:NTHI) is the clinical-data redirect. NEO100 in recurrent brain cancer posted a 21% response rate against a historical average below 8%, with 44% of patients reaching six-month progression-free survival versus a 21% to 31% historical band. The FDA cleared NEO212 for Phase II, the NIH layered in $2.5 million of non-dilutive funding, and a $50 million strategic partnership with Quazar Investment opens a Middle East channel through the NuroMENA subsidiary."
"Plus Therapeutics ( NASDAQ:PSTV) is the commercial-traction redirect. The CNSide diagnostic now carries national coverage with UnitedHealthcare and Humana for a combined roughly 67 million covered lives, holds CLIA certification, and is licensed in 49 of 50 states. Plus secured an AMA Category III CPT reimbursement code, a $17.6 million CPRIT grant, and a"
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]